Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

ctDNA Helps Predict Recurrence in Real-World Analysis of Patients With Resected CRC

October 21st 2022

Stacey A. Cohen, MD, discusses the results of real-world analysis of patients with resected stage I-III colorectal cancer, how circulating tumor DNA status correlated with recurrence rates, and how these real-world data compared with previous observational studies.

A Newly Identified Genetic Mutation May Be Key to Developing Thymic Cancer Treatment

October 19th 2022

Recent developments in cancers of the thymus, a small organ located in the mediastinum above the heart, have shined a light on a malignancy that only affects about 400 Americans annually.

Futibatinib Approval Expands Options for Patients With FGFR2+ Cholangiocarcinoma

October 19th 2022

The accelerated approval of the FGFR inhibitor futibatinib on September 30, 2022, has expanded options for previously treated adult patients with unresectable, locally advanced, or metastatic intrahepatic cholangiocarcinoma FGFR2 fusions or rearrangements.1

Dr. Yorio on the Safety of Targeted Therapies in BRAF-Mutated Melanoma

October 18th 2022

Jeff Yorio, MD, discusses adverse effects associated with targeted agents and combinations in BRAF-mutated melanoma.

Dr. Bhalla on Unmet Needs in the Treatment of EGFR Exon 20–Mutant NSCLC

October 17th 2022

Sheena Bhalla, MD, discusses the need for improved understanding of EGFR exon 20 insertion mutations in the development of non–small cell lung cancer treatment.

Dr. Yorio on Treatment Combinations in BRAF-Mutated Melanoma

October 13th 2022

Jeff Yorio, MD, discusses treatment combinations in BRAF-mutated melanoma.

Targeted Therapy Combinations Provide Multiple Treatment Options in BRAF-Mutated Melanoma

October 12th 2022

Jeff Yorio, MD, discussed the decision-making process for treating patients with BRAF-mutant melanoma, the use of immunotherapy in melanoma, and the management of cutaneous squamous cell carcinoma and basal cell carcinoma.

Gilteritinib Induces Encouraging Responses in Newly Diagnosed FLT3-Mutated AML

October 9th 2022

Gilteritinib, in combination with induction and consolidation chemotherapy, generated responses in patients with newly diagnosed acute myeloid leukemia, including those with FLT3 mutations, according to data from a phase 1 trial.

Increasingly Sensitive Genetic Testing Advances GI Cancer Diagnosis and Management

October 8th 2022

John Lindsay Marshall, MD, discusses past, present, and future developments in molecular testing, as well as the unique offerings of tissue and blood tests and the ways in which these precise approaches will ultimately make cancer diagnosis and treatment more efficient and effective.

Neratinib Elicits Durable Responses in Metastatic or Recurrent HER2-Mutated Cervical Cancer

October 6th 2022

Single-agent neratinib produced robust responses in patients with metastatic or recurrent HER2-mutated cervical cancer, according to updated data from phase 2 SUMMIT basket trial.

Sapanisertib Gets FDA Fast Track Status for Pretreated NRF2-Mutated Squamous NSCLC

October 4th 2022

The FDA has granted a fast track designation to sapanisertib as a potential therapeutic option in patients with unresected or metastatic squamous non–small cell lung cancer whose tumors harbor an NRF2 mutation and who have previously received platinum-based chemotherapy and immune checkpoint inhibition.

FDA Green Lights Companion Diagnostic for Trastuzumab Deruxtecan in Metastatic HER2-Low Breast Cancer

October 4th 2022

The FDA has approved use of the PATHWAY anti-HER2/neu rabbit monoclonal primary antibody as a companion diagnostic to identify patients with HER2-low metastatic breast cancer who are eligible for treatment with trastuzumab deruxtecan.

FDA Approves Futibatinib for FGFR2+ Cholangiocarcinoma

September 30th 2022

The FDA has granted an accelerated approval to futibatinib (Lytgobi) for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements.

FDA Greenlights Companion Diagnostic for Selpercatinib in RET+ NSCLC and Thyroid Cancers

September 29th 2022

The FDA has approved the Oncomine Dx Target Test as a companion diagnostic to select patients with RET fusion–positive locally advanced or metastatic non–small cell lung cancer, advanced or metastatic thyroid cancer, and advanced or metastatic medullary thyroid cancer who could be candidates to receive selpercatinib.

TAC01-HER2 Showcases Early Clinical Activity in HER2-Overexpressed Solid Tumors

September 25th 2022

TAC01-HER2 demonstrated early signals of clinical activity with a tolerable safety profile in patients with HER2-overexpressed solid tumors.

Clinical Trials Aim to Bring Zenocutuzumab to Patients with NRG1+ Cancers

September 22nd 2022

Blocking ligand interaction of HER2 and HER3 in patients with NRG1 fusion–positive tumors has demonstrated a clinically feasible avenue to improve outcomes with the novel agent zenocutuzumab.

FDA Approves Selpercatinib for Locally Advanced or Metastatic RET Fusion+ Solid Tumors

September 21st 2022

The FDA has granted accelerated approval to selpercatinib for adult patients with locally advanced or metastatic solid tumors harboring a RET gene fusion that have progressed on or after previous systemic treatment or who have no satisfactory alternative treatment options.

FDA Grants Regular Approval to Selpercatinib for Locally Advanced or Metastatic RET+ NSCLC

September 21st 2022

The FDA has granted a regular approval to selpercatinib (Retevmo) for adult patients with locally advanced or metastatic non–small cell lung cancer harboring a RET gene fusion, as detected by an FDA-approved test.

Alpelisib Displays Clinical Benefit in Pediatric PIK3CA-Related Overgrowth Spectrum Disease

September 21st 2022

Alpelisib decreased the need for surgery and led to improvements in performance status and disease-related signs and symptoms in pediatric patients with PIK3CA-related overgrowth spectrum disease who received treatment with the PI3K inhibitor under compassionate use.

Pemigatinib Represents Transformative Treatment for Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement

September 13th 2022

Srdan Verstovsek, MD, PhD, discusses the clinical implications of the FDA approval of pemigatinib, the results of the FIGHT-203 trial, and the need to conduct chromosomal analysis for patients with myeloid/lymphoid neoplasms.